Streetbeat News

RHHBY

Roche Holding AG

CEO

Severin Schwan

Industry

Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

Open

42.57

Mkt cap

278B

Volume

213K

High

43.31

P/E Ratio

29.63

52-wk high

43.96

Low

42.56

Div yield

N/A

52-wk low

29.20

Tempest Therapeutics Inc. (NASDAQ:TPST) stock surged due to a new agreement with Roche Holdings AG to advance a Phase 3 trial for liver cancer treatment. The trial will evaluate the combination of amezalpat with atezolizumab and bevacizumab. Tempest retains all rights to amezalpat, and the stock rose 23% in premarket trading.

Portfolio Pulse from Vandana Singh

October 10, 2024 | 1:06 pm

Tempest Therapeutics has entered into an agreement with Roche to advance the evaluation of a combination therapy involving amezalpat and atezolizumab. Tempest will lead the pivotal study, while Roche will supply atezolizumab. Tempest retains all rights to amezalpat.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2024 | 11:03 am

Bio-Path Holdings, Inc. (NASDAQ:BPTH) is seeing a significant stock price increase as it initiates a new obesity program using its DNAbilize technology, originally developed for blood cancer. The company plans preclinical studies in late 2024 to explore the drug's potential for treating obesity and Type 2 diabetes. Additionally, Bio-Path has completed enrollment in a clinical trial for BP1002 targeting acute myeloid leukemia, aiming to address venetoclax resistance.

Portfolio Pulse from Vandana Singh

October 08, 2024 | 1:27 pm

Scholar Rock's apitegromab shows promising results in a Phase 3 trial for spinal muscular atrophy, leading to a significant stock price increase. The company plans to submit FDA and European marketing applications in 2025.

Portfolio Pulse from Vandana Singh

October 07, 2024 | 2:23 pm

The U.S. may have reached a turning point in its fight against obesity, with new weight loss drugs like Ozempic and Wegovy contributing to a decline in obesity rates. Novo Nordisk, Eli Lilly, and Roche Holdings are key players in this pharmaceutical shift.

Portfolio Pulse from Benzinga Neuro

October 07, 2024 | 2:46 am

Roche Holdings AG is accelerating the development of its obesity drug CT-388, aiming for over $3 billion in sales. The company is also cutting drug development costs and time, with plans to launch 20 transformative medicines by 2030. Roche is expanding its portfolio with a $850 million acquisition from Regor Pharmaceuticals.

Portfolio Pulse from Vandana Singh

September 30, 2024 | 3:39 pm

Genentech, part of Roche Group, announced positive Phase III results for Gazyva in treating lupus nephritis, showing improved renal response and potential to delay kidney disease progression. The findings could offer a new treatment option for lupus patients.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2024 | 6:44 am

Roche's phase 3 CENTERSTONE study shows that Xofluza, an antiviral drug, significantly reduces the transmission of influenza viruses. The study met its primary endpoint, indicating a single dose can prevent household transmission. This adds to Xofluza's benefits, which is already approved for treating and preventing influenza. The study was partially funded by US federal agencies.

Portfolio Pulse from Vandana Singh

September 19, 2024 | 4:13 pm

Roche's Genentech has announced that its Phase III CENTERSTONE study of Xofluza shows a significant reduction in the transmission of influenza viruses. This is the first antiviral for respiratory viral illness to demonstrate such a benefit in a global Phase III study, potentially easing the burden on healthcare systems.

Portfolio Pulse from Benzinga Newsdesk

September 19, 2024 | 6:03 am

Roche Holdings AG received FDA approval for two subcutaneous injections: Ocrevus Zunovo for multiple sclerosis and Tecentriq Hybreza for various cancers. These approvals offer faster administration times compared to traditional IV methods.

Portfolio Pulse from Vandana Singh

September 16, 2024 | 3:23 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.